Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC